New drug riliprubart tested for Long-Term control of nerve disease CIDP
NCT ID NCT06859099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving the drug for up to 3 years to see if it remains safe and effective. The goal is to see if riliprubart can help prevent relapses and manage the disease over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
riliprubart (a drug given as a subcutaneous injection)
What this could lead to
If successful, this could show that riliprubart is a safe and effective long-term treatment option for people with CIDP, potentially reducing relapses and the need for other therapies.
What could go wrong
This is an extension study, so participants already know the drug works for them. It is not a placebo-controlled trial, so results may not apply to all CIDP patients. Long-term side effects are still being monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYNEUROPATHY, INFLAMMATORY DEMYELINATING, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama Neurology Associates- Site Number : 8400019
Homewood, Alabama, 35209, United States
-
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004
Ribeirão Preto, São Paulo, 14049-900, Brazil
-
Investigational Site Number : 0320003
Buenos Aires, 1221, Argentina
-
Investigational Site Number : 1240001
Gatineau, Quebec, J8Y 1W2, Canada
-
Investigational Site Number : 1240002
Québec, Quebec, G1E 7G9, Canada
-
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, 8207257, Chile
-
Investigational Site Number : 1520003
Lo Barnechea, Reg Metropolitana de Santiago, 7691236, Chile
-
Investigational Site Number : 1560001
Shanghai, 200040, China
-
Investigational Site Number : 1560002
Fuzhou, 350001, China
-
Investigational Site Number : 1560003
Wuhan, 430030, China
-
Investigational Site Number : 1560005
Beijing, 100053, China
-
Investigational Site Number : 1560006
Wuhan, 430060, China
-
Investigational Site Number : 1560011
Chengdu, 610072, China
-
Investigational Site Number : 1560012
Guangzhou, 510000, China
-
Investigational Site Number : 1560013
Beijing, 100034, China
-
Investigational Site Number : 2030001
Prague, 128 08, Czechia
-
Investigational Site Number : 2030004
Brno, 625 00, Czechia
-
Investigational Site Number : 2080002
Aarhus, 8200, Denmark
-
Investigational Site Number : 2500001
Le Kremlin-Bicêtre, 94270, France
-
Investigational Site Number : 2500002
Marseille, 13885, France
-
Investigational Site Number : 2500004
Paris, 75013, France
-
Investigational Site Number : 2500005
Toyama, 939-2716, Japan
-
Investigational Site Number : 2500007
Bordeaux, 33076, France
-
Investigational Site Number : 2760002
Göttingen, 37075, Germany
-
Investigational Site Number : 2760004
Tübingen, 72076, Germany
-
Investigational Site Number : 3800001
Milan, Milano, 20132, Italy
-
Investigational Site Number : 3800002
Rome, Roma, 00168, Italy
-
Investigational Site Number : 3800003
Genoa, Genova, 16132, Italy
-
Investigational Site Number : 3800004
Rozzano, Milano, 20089, Italy
-
Investigational Site Number : 3800005
Pavia, 27100, Italy
-
Investigational Site Number : 3800007
Pisa, 56126, Italy
-
Investigational Site Number : 3920011
Bunkyo-Ku, Tokyo, 113-8510, Japan
-
Investigational Site Number : 3920012
Higashi-Matsuyama, Saitama, 355-0005, Japan
-
Investigational Site Number : 4100003
Seoul, Seoul-teukbyeolsi, 02841, South Korea
-
Investigational Site Number : 5280001
Amsterdam, 1105 AZ, Netherlands
-
Investigational Site Number : 6160001
Lublin, Lublin Voivodeship, 20-954, Poland
-
Investigational Site Number : 6200004
Lisbon, 1150-199, Portugal
-
Investigational Site Number : 6880001
Belgrade, 11000, Serbia
-
Investigational Site Number : 7240001
Barcelona, Catalunya [Cataluña], 08041, Spain
-
Investigational Site Number : 7240002
Barcelona, 08035, Spain
-
Investigational Site Number : 7240003
Valencia, 46026, Spain
-
Investigational Site Number : 7240004
Majadahonda, Madrid, 28222, Spain
-
Investigational Site Number : 7240008
Málaga, 29010, Spain
-
Investigational Site Number : 7520001
Stockholm, 113 65, Sweden
-
Investigational Site Number : 7920003
Konya, 42075, Turkey (Türkiye)
-
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022
Philadelphia, Pennsylvania, 19104, United States
-
University of Kansas Medical Center- Site Number : 8400010
Kansas City, Kansas, 66160, United States